Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

被引：4
|
作者：
Kelley, Robin Kate
Rimassa, Lorenza
Ryoo, Baek-Yeol
Park, Joong-Won
Blanc, Jean-Frederic
Chan, Stephen Lam
Dadduzio, Vincenzo
Yau, Thomas Cheung
Sen, Suvajit
Markby, David W.
Kaldate, Rajesh
El-Khoueiry, Anthony B.
Cheng, Ann-Lii
Meyer, Tim
Abou-Alfa, Ghassan K.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Humanitas Clin & Res Ctr, Rozzano, Italy
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Natl Canc Ctr Korea, Goyang Si, South Korea
[5] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[6] Chinese Univ Hong Kong, State Key Lab Oncol South China, Dept Clin Oncol, Hong Kong, Peoples R China
[7] IRCCS, Ist Oncol Veneto, Padua, Italy
[8] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[9] Exelixis Inc, Alameda, CA USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Alpha Fetoprotein (AFP) Response and Efficacy Outcomes in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)
    Waidmann, Oliver
    Kelley, R. K.
    Rimassa, L.
    Ryoo, B. Y.
    Blanc, J. F.
    Chan, S. L.
    Zagonel, V.
    Yau, T.
    Sen, S.
    Markby, D. W.
    Kaldate, R.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 59 - 59
  • [2] Alpha fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Rimassa, L.
    Ryoo, B. -Y.
    Blanc, J. -F.
    Chan, S. L.
    Zagonel, V.
    Yau, T.
    Sen, S.
    Markby, D. W.
    Kaldate, R.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 125
  • [3] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    El-Khoueiry, A. B.
    Meyer, T.
    Rimassa, L.
    Merle, P.
    Chan, S. L.
    Tran, A.
    Parnis, F.
    Tam, V. C.
    Cattan, S.
    Markby, D. W.
    Clary, D. O.
    Cheng, A-L.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y.
    Cicin, I.
    Harris, W. P.
    Banu, E.
    Sarker, D.
    Tan, B.
    van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Outcomes By Baseline Alpha-Fetoprotein (AFP) Levels in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Previously Treated Advanced Hepatocellular Carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    El-Khoueiry, Anthony B.
    Meyer, Timothy
    Rimassa, Lorenza
    Merle, Philippe
    Chan, Stephen L.
    Tran, Albert
    Parnis, Francis
    Tam, Vincent C.
    Cattan, Stephane
    Markby, David W.
    Clary, Douglas O.
    Cheng, Ann-Lii
    Kelley, Robin Kate
    HEPATOLOGY, 2018, 68 : 533A - 534A
  • [6] Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Blanc, J. F.
    Meyer, T.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Cicin, I.
    Chen, Y.
    Bolondi, L.
    Dadduzio, V.
    Baron, A.
    Lin, Z-Z.
    Adriani, J.
    Kelly, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 237 - 237
  • [7] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
  • [8] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [9] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Cicin, Irfan
    Blanc, Jean-Frederic
    Klumpen, Heinz Josef
    Zagonel, Vittorina
    Tran, Albert
    Kim, Stefano Chong Hun
    Lin, Zhong-Zhe
    Tam, Vincent C.
    Hazra, Saswati
    Mangeshkar, Milan
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345